Related Experiment Video

Updated: May 19, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

[Prevalence of CYP2C19 polymorphisms involved in clopidogrel metabolism in Fujian Han population]

Wei Wei1, Ling Fang, Ning Wang

  • 1Department of Neurology, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics
|August 10, 2012
PubMed

Insights

The frequency of CYP2C19 genetic variations, crucial for clopidogrel metabolism, was studied in Fujian Han Chinese. These variations influence drug response and show distinct ethnic distributions.

Area of Science:

  • Pharmacogenomics
  • Genetic Epidemiology

Background:

  • Clopidogrel is an antiplatelet medication whose efficacy is influenced by CYP2C19 genetic variations.
  • Understanding the prevalence of these variations is essential for personalized medicine and optimizing clopidogrel therapy.

Purpose of the Study:

  • To determine the frequencies of key CYP2C19 polymorphisms (*2, *3, and *17) in the Fujian Han Chinese population.
  • To compare these frequencies with other ethnic groups globally.

Main Methods:

  • Genotyping of 1001 Fujian Han volunteers using polymerase chain reaction-restriction fragment length polymorphism and direct sequencing.
  • Analysis of CYP2C19*2, *3, and *17 allele frequencies.

Main Results:

  • CYP2C19*2, *3, and *17 allele frequencies were 32.4%, 5.8%, and 0.4%, respectively.
  • Intermediate and poor metabolizers constituted 47.95% and 13.99% of the study cohort.
  • Frequencies were similar to East and Southeast Asian populations but differed significantly from Central Asian, European, South American, and African populations.

Conclusions:

  • Significant ethnic and regional variations exist in CYP2C19 polymorphism prevalence.
  • Fujian Han Chinese exhibit higher frequencies of intermediate and poor metabolizers compared to certain Central Asian, European, and African populations.
  • These findings highlight the importance of considering genetic diversity in clopidogrel pharmacotherapy.
Abstract

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...